Association of Anti-CCAR1 Autoantibodies With Decreased Cancer Risk Relative to the General Population in Patients With Anti–Transcriptional Intermediary Factor 1γ–Positive Dermatomyositis

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: To describe the disease specificity, clinical phenotype, and risk of cancer in dermatomyositis (DM) patients with autoantibodies against cell division cycle and apoptosis regulator protein 1 (anti-CCAR1). Methods: The frequency of anti-CCAR1 autoantibodies was measured by enzyme-linked immunosorbent assay in the serum of DM patients from 2 independent cohorts (Johns Hopkins and Stanford), with patients with several other rheumatic diseases and healthy controls used as comparators. Clinical features and the risk of cancer incidence relative to that in the general population were determined in anti-CCAR1–positive DM patients. Results: Anti-CCAR1 antibodies were significantly associated with anti–transcriptional intermediary factor 1γ (anti-TIF1γ) antibodies present in the serum of patients with DM: 80 (32%) of 252 anti-TIF1γ–positive DM patients versus 14 (8%) of 186 anti-TIF1γ–negative DM patients were positive for anti-CCAR1 antibodies (P < 0.001). Anti-CCAR1 antibodies were not detected in any of the 32 serum samples from healthy controls, and were present at very low frequencies in the sera of patients with other rheumatic diseases: 1 (2.3%) of 44 patients with anti–hydroxymethylglutaryl-coenzyme A reductase–positive necrotizing myopathy, 1 (2.3%) of 44 patients with inclusion body myositis, and 3 (6.5%) of 46 patients with systemic lupus erythematosus were positive for anti-CCAR1 antibodies. Upon examining data on occurrence of cancer from the onset of DM onward, the observed number of cancers diagnosed in anti–TIF-1γ–positive DM patients was significantly greater than expected in both cohorts, with a standardized incidence ratio (SIR) of 3.49 (95% confidence interval [95% CI] 2.39–4.92) in the Johns Hopkins cohort and a SIR of 4.54 (95% CI 3.04–6.52) in the Stanford cohort (each P < 0.001). DM patients who were both anti-TIF1γ positive and anti-CCAR1 positive had lower SIRs for cancer, with a SIR of 1.78 (95% CI 0.77–3.51) (P = 0.172) in the Johns Hopkins cohort and a SIR of 1.61 (95% CI 0.44–4.13) (P = 0.48) in the Stanford cohort. Conclusion: Anti-CCAR1 autoantibodies are specific for anti-TIF1γ–positive DM. Their presence in anti-TIF1γ–positive patients attenuates the risk of cancer to a level comparable to that seen in the general population. (Figure presented.).

Original languageEnglish (US)
Pages (from-to)1238-1245
Number of pages8
JournalArthritis and Rheumatology
Volume75
Issue number7
DOIs
StatePublished - Jul 2023

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology

Fingerprint

Dive into the research topics of 'Association of Anti-CCAR1 Autoantibodies With Decreased Cancer Risk Relative to the General Population in Patients With Anti–Transcriptional Intermediary Factor 1γ–Positive Dermatomyositis'. Together they form a unique fingerprint.

Cite this